LABF.F logo

Laboratorios Farmaceuticos Rovi OTCPK:LABF.F Stock Report

Last Price

US$65.86

Market Cap

US$3.3b

7D

0%

1Y

n/a

Updated

19 Dec, 2024

Data

Company Financials +

Laboratorios Farmaceuticos Rovi, S.A.

OTCPK:LABF.F Stock Report

Market Cap: US$3.3b

LABF.F Stock Overview

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. More details

LABF.F fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance3/6
Financial Health5/6
Dividends4/6

My Notes

Capture your thoughts, links and company narrative

Laboratorios Farmaceuticos Rovi, S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Laboratorios Farmaceuticos Rovi
Historical stock prices
Current Share Price€65.86
52 Week High€90.61
52 Week Low€65.86
Beta0.49
1 Month Changen/a
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO20.74%

Recent News & Updates

Recent updates

Shareholder Returns

LABF.FUS PharmaceuticalsUS Market
7D0%-2.1%-4.0%
1Yn/a9.1%24.0%

Return vs Industry: Insufficient data to determine how LABF.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how LABF.F performed against the US Market.

Price Volatility

Is LABF.F's price volatile compared to industry and market?
LABF.F volatility
LABF.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement10.5%
Market Average Movement6.4%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: LABF.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine LABF.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19462,137Juan Lopez-Belmonte Encinawww.rovi.es

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi.

Laboratorios Farmaceuticos Rovi, S.A. Fundamentals Summary

How do Laboratorios Farmaceuticos Rovi's earnings and revenue compare to its market cap?
LABF.F fundamental statistics
Market capUS$3.29b
Earnings (TTM)US$171.00m
Revenue (TTM)US$828.32m

19.2x

P/E Ratio

4.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LABF.F income statement (TTM)
Revenue€799.25m
Cost of Revenue€310.33m
Gross Profit€488.92m
Other Expenses€323.92m
Earnings€165.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)3.23
Gross Margin61.17%
Net Profit Margin20.64%
Debt/Equity Ratio20.1%

How did LABF.F perform over the long term?

See historical performance and comparison

Dividends

1.8%

Current Dividend Yield

39%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 16:11
End of Day Share Price 2024/11/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Laboratorios Farmaceuticos Rovi, S.A. is covered by 18 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Álvaro Arístegui EchevarríaAhorro Corporación
Guilherme SampaioBanco BPI, S.A.
Javier Esteban LarioBanco de Sabadell. S.A.